Trial Profile
High-dose, pulsatile erlotinib after progression on standard dose erlotinib in EGFR-mutated NSCLC patients.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PE-study
- 27 Sep 2012 New trial record